{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:29:16Z","timestamp":1773275356318,"version":"3.50.1"},"reference-count":31,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Context: Despite accounting for variations in gland size and iodine kinetics, the success of radioiodine therapy in patients with Graves\u2019 disease remains moderately common and unpredictable.<\/jats:p>\n               <jats:p>Objectives: We hypothesized that hypoechogenic glands, with large, densely packed cells, are more radiosensitive than normoechogenic glands, in which much radiation is wasted on more abundant colloid. We evaluated this hypothesis in a cohort of patients with Graves\u2019 disease.<\/jats:p>\n               <jats:p>Design: This was a prospective trial of patients recruited during 4 yr and followed up 1 yr after radioiodine therapy.<\/jats:p>\n               <jats:p>Setting: This trial was held in a university hospital-outpatient clinic.<\/jats:p>\n               <jats:p>Patients: A total of 177 consecutive patients with first presentation of Graves\u2019 disease (28 males), 23\u201376 yr old, who relapsed after antithyroid therapy were included in the study.<\/jats:p>\n               <jats:p>Intervention: The patients were assigned to an ablative target-absorbed dose of 200 Gy (n = 78) or randomly to 100 or 120 Gy of nonablative dose (n = 99).<\/jats:p>\n               <jats:p>Main Outcome Measures: The measures were incidences of hyperthyroidism, euthyroidism, and hypothyroidism at 12-month follow-up.<\/jats:p>\n               <jats:p>Results: At follow-up there were 25 hyperthyroid, 44 euthyroid, and 108 hypothyroid patients. Compared with 96 patients with a hypoechogenic gland, in 81 patients with a normoechogenic gland, there were more hyperthyroid (22 vs. 7%) and euthyroid (41 vs. 11%), but less hypothyroid outcomes (37 vs. 81%; P &amp;lt; 0.0001). The other independent predictor of increased radioresistance was the large gland volume.<\/jats:p>\n               <jats:p>Conclusion: In patients with Graves\u2019 disease, normoechogenic and large glands are associated with increased radioresistance.<\/jats:p>","DOI":"10.1210\/jc.2007-0879","type":"journal-article","created":{"date-parts":[[2007,7,4]],"date-time":"2007-07-04T00:41:42Z","timestamp":1183509702000},"page":"3547-3552","source":"Crossref","is-referenced-by-count":36,"title":["Thyroid Echogenicity Predicts Outcome of Radioiodine Therapy in Patients with Graves\u2019 Disease"],"prefix":"10.1210","volume":"92","author":[{"given":"Vinko","family":"Markovic\u0301","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine (V.M., D.E.), University Hospital Split, 21 000 Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davor","family":"Eterovic\u0301","sequence":"additional","affiliation":[{"name":"Department of Medical Physics and Biophysics (D.E.), Split University School of Medicine, 21 000 Split, Croatia"},{"name":"Department of Nuclear Medicine (V.M., D.E.), University Hospital Split, 21 000 Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071614162525900_R1","first-page":"982","article-title":"Graves\u2019 disease: general considerations","author":"Woeber","year":"1986","journal-title":"In: Ingbar SH, Braverman LE, eds. Werner\u2019s the thyroid: a fundamental and clinical text. 5th ed. Philadelphia: Lippincott;"},{"key":"2020071614162525900_R2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","article-title":"Clinical features of patients with Graves\u2019 disease undergoing remission after antithyroid drug treatment.","volume":"7","author":"Vitti","year":"1997","journal-title":"Thyroid"},{"key":"2020071614162525900_R3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2265.1995.tb02039.x","article-title":"Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile?","volume":"43","author":"Jarlov","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614162525900_R4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2265.1991.tb01738.x","article-title":"Long-term follow-up of treatment of thyrotoxicosis by three different methods.","volume":"34","author":"Franklyn","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614162525900_R5","first-page":"411","article-title":"Optimal iodine-131 dose for eliminating hyperthyroidism in Graves\u2019 disease.","volume":"32","author":"Nordyke","year":"1991","journal-title":"J Nucl Med"},{"key":"2020071614162525900_R6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2265.1988.tb03683.x","article-title":"Outcome following standardized 185 MBq dose 131I therapy for Graves\u2019 disease.","volume":"28","author":"Watson","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614162525900_R7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/thy.1997.7.247","article-title":"Treatment of Graves\u2019 hyperthyroidism with radioiodine: results of a prospective randomized trial.","volume":"7","author":"Peters","year":"1997","journal-title":"Thyroid"},{"key":"2020071614162525900_R8","first-page":"40","article-title":"Outcome of thyroid function in Graves\u2019 patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.","volume":"83","author":"Chiovato","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614162525900_R9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-2000-5807","article-title":"Radioiodine therapy in Graves\u2019 hyperthyroidism: determination of the individual optimum target dose.","volume":"108","author":"Haase","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2020071614162525900_R10","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s002590100565","article-title":"Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves\u2019 disease and toxic nodular goiter?","volume":"28","author":"Ko\u0308rber","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"2020071614162525900_R11","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s002590100621","article-title":"Determination of optimal minimum radioiodine dose in patients with Graves\u2019 disease: a clinical outcome study.","volume":"28","author":"Howarth","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"2020071614162525900_R12","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s00259-002-0877-3","article-title":"Radioiodine therapy in Graves\u2019 disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.","volume":"29","author":"Reinhardt","year":"2002","journal-title":"Eur J Nucl Med"},{"key":"2020071614162525900_R13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1089\/thy.1999.9.865","article-title":"Calculation of the radioiodine dose for the treatment of Graves\u2019 hyperthyroidism: is more than seven-thousand rad target dose necessary?","volume":"9","author":"Bajnok","year":"1999","journal-title":"Thyroid"},{"key":"2020071614162525900_R14","first-page":"1038","article-title":"Age and gender predict the outcome of treatment for Graves\u2019 hyperthyroidism.","volume":"85","author":"Allahabadia","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614162525900_R15","first-page":"3611","article-title":"Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.","volume":"86","author":"Allahabadia","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614162525900_R16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1507\/endocrj.51.127","article-title":"Onset age is associated with outcome in radioiodine therapy of Graves\u2019 disease.","volume":"51","author":"Yamashita","year":"2004","journal-title":"Endocr J"},{"key":"2020071614162525900_R17","first-page":"1229","article-title":"Success rate of radioiodine therapy in Graves\u2019 disease: the influence of thyrostatic medication.","volume":"84","author":"Sabri","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614162525900_R18","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/thy.1999.9.1181","article-title":"Radioiodine therapy in Graves\u2019 disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.","volume":"9","author":"Sabri","year":"1999","journal-title":"Thyroid"},{"key":"2020071614162525900_R19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2265.1997.2741075.x","article-title":"The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves\u2019 disease.","volume":"47","author":"Hancock","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614162525900_R20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/thy.1995.5.243","article-title":"Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive radioiodine alone in Graves\u2019 disease.","volume":"5","author":"Tuttle","year":"1995","journal-title":"Thyroid"},{"key":"2020071614162525900_R21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.7326\/0003-4819-118-3-199302010-00009","article-title":"The risk of determining risk with multivariate models.","volume":"118","author":"Concato","year":"1993","journal-title":"Ann Intern Med"},{"key":"2020071614162525900_R22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/BF01733114","article-title":"Sonographic tissue characterisation in thyroid gland diagnosis. A correlation between sonography and histology.","volume":"63","author":"Mu\u0308ller","year":"1985","journal-title":"Klin Wochenschr"},{"key":"2020071614162525900_R23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1365-2265.1996.d01-1563.x","article-title":"Thyroid hypoechogenicity after methimazole withdrawal in Graves\u2019 disease: a useful index for predicting recurrence?","volume":"45","author":"Zingrillo","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6 Pt 1","key":"2020071614162525900_R24","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI102194","article-title":"Dosage determination in the use of radioactive isotopes","volume":"28","author":"Marinelli","year":"1949","journal-title":"J Clin Invest"},{"key":"2020071614162525900_R25","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What\u2019s the relative risk: a method of correcting odds ratio in cohort studies of common outcomes.","volume":"280","author":"Zhang","year":"1998","journal-title":"JAMA"},{"key":"2020071614162525900_R26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1530\/acta.0.1260128","article-title":"Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves\u2019 disease.","volume":"126","author":"Vitti","year":"1992","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071614162525900_R27","first-page":"3488","article-title":"The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves\u2019 hyperthyroidism: one year follow up of a prospective randomized study.","volume":"86","author":"Andrade","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614162525900_R28","first-page":"24","article-title":"Anatomy and histochemistry","author":"Halmi","year":"1986","journal-title":"In: Ingbar SH, Braverman LE, eds. Werner\u2019s the thyroid: a fundamental and clinical text. 5th ed. Philadelphia: Lippincott;"},{"key":"2020071614162525900_R29","first-page":"345","article-title":"Biologic effects of radioiodines on the human thyroid gland","author":"Maxon","year":"2000","journal-title":"In: Braverman LE, Utiger RD, eds. Werner & Ingbar\u2019s the thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lippincott;"},{"key":"2020071614162525900_R30","author":"Oertel","year":"1986"},{"key":"2020071614162525900_R31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/BF03347356","article-title":"Croatia has reached iodine sufficiency.","volume":"26","author":"Kusic","year":"2003","journal-title":"J Endocrinol Invest"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/9\/3547\/10405394\/jcem3547.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/92\/9\/3547\/10405394\/jcem3547.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:49:30Z","timestamp":1594950570000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/92\/9\/3547\/2597850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,1]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-0879","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,1]]}}}